


## FLT3-IN-4

<b>Cat. No.:</b>	HY-128571		
<b>CAS No.:</b>	2304799-09-3		
<b>Molecular Formula:</b>	C <sub>23</sub> H <sub>25</sub> N <sub>7</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	431.49		
<b>Target:</b>	FLT3		
<b>Pathway:</b>	Protein Tyrosine Kinase/RTK		
<b>Storage:</b>	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 25 mg/mL (57.94 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.3176 mL	11.5878 mL	23.1755 mL
5 mM	0.4635 mL	2.3176 mL	4.6351 mL
10 mM	0.2318 mL	1.1588 mL	2.3176 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC<sub>50</sub>=7 nM) inhibitor for treating acute myelogenous leukemia<sup>[1]</sup>.

#### In Vitro

FLT3-IN-4 (Compound 9u) shows potent inhibitory activities against MV4-11 and Molm-13 cells with IC<sub>50</sub> values are 0.089±0.001 nM and 0.022±0.003 nM, respectively<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Yuan X, et al. Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia. J Med Chem. 2019 Apr 25;62(8):4158-4173.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA